NASDAQ:TCON - TRACON Pharmaceuticals Stock Price, News & Analysis

$0.52
0.00 (0.00 %)
(As of 08/25/2019 01:18 AM ET)
Today's Range
$0.50
Now: $0.52
$0.5320
50-Day Range
$0.42
MA: $0.52
$0.63
52-Week Range
$0.40
Now: $0.52
$2.35
Volume64,829 shs
Average Volume97,329 shs
Market Capitalization$15.57 million
P/E RatioN/A
Dividend YieldN/A
Beta2.45
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCON
CUSIPN/A
Phone858-550-0780

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3 million
Book Value$0.30 per share

Profitability

Net Income$-34,960,000.00

Miscellaneous

Employees26
Market Cap$15.57 million
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable

Receive TCON News and Ratings via Email

Sign-up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter.


TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals Inc (NASDAQ:TCON) released its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.02. View TRACON Pharmaceuticals' Earnings History.

When is TRACON Pharmaceuticals' next earnings date?

TRACON Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for TRACON Pharmaceuticals.

What price target have analysts set for TCON?

2 brokerages have issued 12-month price objectives for TRACON Pharmaceuticals' shares. Their forecasts range from $7.00 to $9.00. On average, they expect TRACON Pharmaceuticals' stock price to reach $8.00 in the next year. This suggests a possible upside of 1,438.5% from the stock's current price. View Analyst Price Targets for TRACON Pharmaceuticals.

What is the consensus analysts' recommendation for TRACON Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TRACON Pharmaceuticals.

Has TRACON Pharmaceuticals been receiving favorable news coverage?

News coverage about TCON stock has trended positive on Sunday, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. TRACON Pharmaceuticals earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for TRACON Pharmaceuticals.

Who are some of TRACON Pharmaceuticals' key competitors?

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include Verastem (VSTM), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Melinta Therapeutics (MLNT), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Conatus Pharmaceuticals (CNAT), Exelixis (EXEL), Novavax (NVAX) and Ocular Therapeutix (OCUL).

Who are TRACON Pharmaceuticals' key executives?

TRACON Pharmaceuticals' management team includes the folowing people:
  • Dr. Charles P. Theuer, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 55)
  • Mr. Scott B. Brown, VP & Head of Fin.
  • Dr. Sharon Real, Exec. VP of Product Devel. (Age 55)
  • Ms. Bonne Adams, Exec. VP of Clinical Operations (Age 42)
  • Ms. Suzy Benedict, Sr. VP of Regulatory Affairs

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.04%), Vanguard Group Inc. (2.94%), BlackRock Inc. (0.18%), Wedbush Securities Inc. (0.16%) and Susquehanna International Group LLP (0.13%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Cross-Border Opportu Puissance and Enterprise Associates 14 New. View Institutional Ownership Trends for TRACON Pharmaceuticals.

Which institutional investors are selling TRACON Pharmaceuticals stock?

TCON stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and BlackRock Inc.. View Insider Buying and Selling for TRACON Pharmaceuticals.

Which institutional investors are buying TRACON Pharmaceuticals stock?

TCON stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Wedbush Securities Inc. and Susquehanna International Group LLP. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Charles Theuer, Cross-Border Opportu Puissance and Enterprise Associates 14 New. View Insider Buying and Selling for TRACON Pharmaceuticals.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $0.52.

How big of a company is TRACON Pharmaceuticals?

TRACON Pharmaceuticals has a market capitalization of $15.57 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-34,960,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. TRACON Pharmaceuticals employs 26 workers across the globe.View Additional Information About TRACON Pharmaceuticals.

What is TRACON Pharmaceuticals' official website?

The official website for TRACON Pharmaceuticals is http://www.traconpharma.com/.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]


MarketBeat Community Rating for TRACON Pharmaceuticals (NASDAQ TCON)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  375
MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote "Outperform" if you believe TCON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCON will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel